The Latest in IT Security

FDA approves new insulin inhaler for diabetics

28
Jun
2014

The US Food and Drug Administration today approved a new insulin inhaler for use in treating diabetes, its first in years. The product, which is made by California-based MannKind Corporation, uses a dry powder that people can breath in to control insulin levels. Its been designed not as a full-time replacement to insulin injections, and instead as an alternative to them at meal times given the powders short-term effects that kick in within what the company says is between 12 to 15 minutes. The drug, which goes by the commercial name Afrezza, is the second such insulin inhaler to get FDA approval, and comes after an earlier version of the device was rejected and sent back for additional testing.

Comments are closed.

Categories

THURSDAY, MARCH 28, 2024
WHITE PAPERS

Mission-Critical Broadband – Why Governments Should Partner with Commercial Operators:
Many governments embrace mobile network operator (MNO) networks as ...

ARA at Scale: How to Choose a Solution That Grows With Your Needs:
Application release automation (ARA) tools enable best practices in...

The Multi-Model Database:
Part of the “new normal” where data and cloud applications are ...

Featured

Archives

Latest Comments